Introduction: The current treatment of non-muscle-invasive bladder cancer is suboptimal. However, in recent years, hyperthermia intravesical chemotherapy (HIVEC) has emerged as a more effective alternative to conventional bladder perfusion. This novel treatment approach appears to have a similar therapeutic effect as Bacillus Calmette-Guérin (BCG) perfusion. This study aims to evaluate the safety and effectiveness of HIVEC compared to conventional bladder perfusion chemotherapy for non-muscle-invasive bladder cancer. Additionally, it aims to evaluate the safety and effectiveness of HIVEC in comparison to BCG perfusion therapy for non-muscle-invasive bladder cancer. Methods: We conducted a comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science databases to gather relevant studies on HIVEC for non-muscle-invasive bladder cancer. The analysis of the collected data was carried out using RevMan 5.3 software. Results: A total of 8 randomized controlled trials were included in this meta-analysis, involving 1,203 patients. Among them, 629 cases received HIVEC, 419 cases received conventional bladder perfusion chemotherapy with mitomycin C, and 155 cases received BCG. The combined analysis revealed that the recurrence rate of bladder hyperthermic perfusion was significantly lower than that of conventional perfusion chemotherapy (RR = 0.65, 95% CI: 0.52, 0.82, p = 0.0003). However, there was no significant difference in recurrence rate between HIVEC and BCG perfusion (RR = 0.78, 95% CI: 0.56, 1.09, p = 0.14). Furthermore, no significant difference was found in the progression rate between the HIVEC group and either the conventional bladder chemotherapy group (RR = 1.08, 95% CI: 0.52, 2.26, p = 0.83) and the BCG perfusion group (RR = 0.48, 95% CI: 0.19, 1.25, p = 0.13). However, compared with the conventional bladder perfusion chemotherapy group, there was no significant statistical difference in adverse events between the bladder hyperthermia chemotherapy group and the conventional bladder perfusion chemotherapy group (RR 1.08, 95% CI: 0.80, 1.45, p = 0.63). No significant difference in the incidence of adverse events was observed between HIVEC and BCG perfusion (RR 1.03, 95% CI: 0.83, 1.29, p = 0.79). Conclusion: The existing results indicate that HIVEC, when compared to conventional bladder perfusion chemotherapy, can lower the recurrence rate of non-muscle-invasive bladder cancer. However, it does not significantly affect the progression rate. There was no statistically significant difference observed in the incidence of adverse events between the use of HIVEC and conventional chemotherapy. Additionally, there was no significant difference in the recurrence rate, progression rate, and incidence of adverse events when compared to BCG.

1.
Bray
F
,
Ferlay
J
,
Soerjomataram
I
,
Siegel
RL
,
Torre
LA
,
Jemal
A
.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
.
CA Cancer J Clin
.
2018
;
68
(
6
):
394
424
.
2.
Ro
JY
,
Staerkel
GA
,
Ayala
AG
.
Cytologic and histologic features of superficial bladder cancer
.
Urol Clin North Am
.
1992
;
19
(
3
):
435
53
.
3.
Chang
SS
,
Boorjian
SA
,
Chou
R
,
Clark
PE
,
Daneshmand
S
,
Konety
BR
, et al
.
Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline
.
J Urol
.
2016
;
196
(
4
):
1021
9
.
4.
Babjuk
M
,
Bohle
A
,
Burger
M
,
Capoun
O
,
Cohen
D
,
Comperat
EM
, et al
.
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016
.
Eur Urol
.
2017
;
71
(
3
):
447
61
.
5.
Tan
WS
,
Rodney
S
,
Lamb
B
,
Feneley
M
,
Kelly
J
.
Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia
.
Cancer Treat Rev
.
2016
;
47
:
22
31
.
6.
Sylvester
RJ
,
van der Meijden
AP
,
Oosterlinck
W
,
Witjes
JA
,
Bouffioux
C
,
Denis
L
, et al
.
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
.
Eur Urol
.
2006
;
49
(
3
):
466
77
; discussion 75-7.
7.
van den Bosch
S
,
Alfred Witjes
J
.
Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review
.
Eur Urol
.
2011
;
60
(
3
):
493
500
.
8.
Page
MJ
,
McKenzie
JE
,
Bossuyt
PM
,
Boutron
I
,
Hoffmann
TC
,
Mulrow
CD
, et al
.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
.
BMJ
.
2021
;
372
:
n71
.
9.
Angulo
JC
,
Alvarez-Ossorio
JL
,
Dominguez
JL
,
Moyano
JL
,
Sousa
A
,
Fernandez
JM
, et al
.
Hyperthermic mitomycin C in intermediate-risk non–muscle-invasive bladder cancer: results of the HIVEC-1 trial
.
Eur Urol Oncol
.
2023
;
6
(
1
):
58
66
.
10.
Arends
TJH
,
Nativ
O
,
Maffezzini
M
,
de Cobelli
O
,
Canepa
G
,
Verweij
F
, et al
.
Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer
.
Eur Urol
.
2016
;
69
(
6
):
1046
52
.
11.
Bhargava
P
.
Adjuvant intravesical chemohyperthermia or conventional chemotherapy in an era of bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer: the HIVEC-II trial
.
Indian J Urol
.
2023
;
39
(
1
):
75
6
.
12.
Colombo
R
,
Da Pozzo
LF
,
Salonia
A
,
Rigatti
P
,
Leib
Z
,
Baniel
J
, et al
.
Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma
.
J Clin Oncol
.
2003
;
21
(
23
):
4270
6
.
13.
Guerrero-Ramos
F
,
Gonzalez-Padilla
DA
,
Gonzalez-Diaz
A
,
de la Rosa-Kehrmann
F
,
Rodriguez-Antolin
A
,
Inman
BA
, et al
.
Recirculating Hyperthermic Intravesical Chemotherapy With Mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial
.
World J Urol
.
2022
;
40
(
4
):
999
1004
.
14.
Sousa
A
,
Gonzalez-Valcarcel
I
,
Mata
JL
,
De La Morena
JM
,
Martinez-Pineiro
L
.
Chemo-resection with hyperthermic intravesical instillation (HIVEC-R) vs standard treatment in patients with intermediate-high risk NMIBC: comparative, prospective, randomized, controled study of efficacy and tolerability: preliminary results
.
J Urol
.
2020
;
203
:
e1123
.
15.
Tan
WS
,
Panchal
A
,
Buckley
L
,
Devall
AJ
,
Loubière
LS
,
Pope
AM
, et al
.
Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette-Guérin therapy (HYMN): a phase III, open-label, randomised controlled trial
.
Eur Urol
.
2019
;
75
(
1
):
63
71
.
16.
Tan
WS
,
Prendergast
A
,
Ackerman
C
,
Yogeswaran
Y
,
Cresswell
J
,
Mariappan
P
, et al
.
Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial
.
Eur Urol
.
2023
;
83
(
6
):
497
504
.
17.
Siegel
RL
,
Miller
KD
,
Fuchs
HE
,
Jemal
A
.
Cancer statistics, 2022
.
CA Cancer J Clin
.
2022
;
72
(
1
):
7
33
.
18.
Xia
C
,
Dong
X
,
Li
H
,
Cao
M
,
Sun
D
,
He
S
, et al
.
Cancer statistics in China and United States, 2022: profiles, trends, and determinants
.
Chin Med J
.
2022
;
135
(
5
):
584
90
.
19.
Jubber
I
,
Ong
S
,
Bukavina
L
,
Black
PC
,
Comperat
E
,
Kamat
AM
, et al
.
Epidemiology of bladder cancer in 2023: a systematic review of risk factors
.
Eur Urol
.
2023
;
84
(
2
):
176
90
.
20.
Gontero
P
,
Sylvester
R
,
Pisano
F
,
Joniau
S
,
Vander Eeckt
K
,
Serretta
V
, et al
.
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients
.
Eur Urol
.
2015
;
67
(
1
):
74
82
.
21.
Rath-Wolfson
L
,
Moskovitz
B
,
Dekel
Y
,
Kugel
V
,
Koren
R
.
Combined intravesical hyperthermia and mitomycin chemotherapy: a preliminary in vivo study
.
Int J Exp Pathol
.
2003
;
84
(
3
):
145
52
.
22.
Paroni
R
,
Salonia
A
,
Lev
A
,
Da Pozzo
LF
,
Cighetti
G
,
Montorsi
F
, et al
.
Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma
.
Br J Clin Pharmacol
.
2001
;
52
(
3
):
273
8
.
23.
Iliakis
G
,
Wu
W
,
Wang
M
.
DNA double strand break repair inhibition as a cause of heat radiosensitization: re-evaluation considering backup pathways of NHEJ
.
Int J Hyperthermia
.
2008
;
24
(
1
):
17
29
.
24.
Neulander
EZ
,
Kaneti
J
.
LONG-TERM outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle invasive bladder cancer (NMIBC)
.
BJU Int
.
2011
;
107
(
10
):
1685
6
. .
25.
Zeng
N
,
Xu
MY
,
Sun
JX
,
Liu
CQ
,
Xu
JZ
,
An
Y
, et al
.
Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: a network meta: analysis
.
Front Oncol
.
2023
;
13
:
1164932
.
26.
de Jong
JJ
,
Hendricksen
K
,
Rosier
M
,
Mostafid
H
,
Boormans
JL
.
Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients
.
Bladder Cancer
.
2018
;
4
(
4
):
395
401
.
27.
Zhou
W
,
Liu
J
,
Mao
D
,
Hu
C
,
Gao
D
.
The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: a meta-analysis
.
PLoS One
.
2022
;
17
(
10
):
e0276453
.
28.
Perera
M
,
Papa
N
,
Christidis
D
,
McGrath
S
,
Manning
T
,
Roberts
M
, et al
.
The impact of the global bacille Calmette-Guerin shortage on treatment patterns: population-based data
.
BJU Int
.
2018
;
121
(
2
):
169
72
.
You do not currently have access to this content.